oxotremorine has been researched along with Hyperplasia in 1 studies
Oxotremorine: A non-hydrolyzed muscarinic agonist used as a research tool.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the muscarine-like acting parasympathomimetic drug oxotremorine and its antagonist atropine on PTH release was tested using single cell suspensions obtained from a) primary parathyroid adenomas, and b) secondary hyperplastic parathyroid tissue from patients undergoing chronic hemodialysis." | 3.67 | The effect of oxotremorine on in-vitro secretion of parathyroid hormone. ( Krause, U; Rothmund, M; Wagner, PK, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wagner, PK | 1 |
| Krause, U | 1 |
| Rothmund, M | 1 |
1 other study available for oxotremorine and Hyperplasia
| Article | Year |
|---|---|
The effect of oxotremorine on in-vitro secretion of parathyroid hormone.
Topics: Adenoma; Cells, Cultured; Humans; Hyperplasia; Oxotremorine; Parathyroid Glands; Parathyroid Hormone | 1987 |